SITC 2026 Preview: Emerging Cancer Immunotherapies and Industry Developments
SITC 2026 at a glance SITC 2026 will spotlight emerging cancer immunotherapies,…
Hematology Strategic Roundup: Earlier-Line Therapies and Competitive Shifts | Sep 18 – Oct 22, 2026
Hematology market trends signal a competitive shift toward earlier-line…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics Professional…
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration Professional…
Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD
Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD…
Hematology Today—December 15, 2025
This week’s hematology update spotlights key developments, regulatory…
Hematology Video Recap—December 1, 2025
This biweekly Hematology video recap highlights recent advancements in…
Hematology Today—November 24, 2025
This week’s hematology update spotlights key developments, regulatory…
Hematology Weekly News - August 25th 2025
🔬🩸 Hematology Updates: CAR-T in Myeloma, Columvi Approved in Canada, New F8…
Multiple myeloma treatment: Why we still need novel scientific research.
Multiple myeloma (MM) is an incurable form of hematological cancer affecting…
